Evidence Table 81. KQ2—Continuous data—Platelet aggregability

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gardner 200723Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean:1.3 Median:SD:6.00%P: | Mean:Median:SD:P: | No difference in groups (p=0.2) | low |
|  |  Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean:-2.7Median:SD:10.00%P: |
| Gardner 200723Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: -1.3Median:SD:12.00%P: | Mean:Median:SD:P: | No difference in groups (p=0.15) | low |
|  |  Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean4.2Median:SD:12.60%P: |

| Evidence Table 81. KQ2—Continuous data—Platelet aggregability (continued) |
| --- |
| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Gardner 200723Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: -4.1Median:SD:14.90%P: | Mean:Median:SD:P: | No difference in groups (p=0.7) | low |
|  |  Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean -6Median:SD:19.60%P: |
| Gardner 200723Parallel | moderate to high | ASA | 325 | ginkgo biloba | 29 |  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: -1.5Median:SD:18.70%P: | Mean:Median:SD:P: | No difference in groups (p=0.3) | low-medium |
|  |  Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean -6.3Median:SD:18.70%P: |
| Steiner 199562Parallel | At high risk for CHD | ASA | 325 | Vitamin E | 25 | platelet adhesion to collagen III | Mean: 2.7Median SD: 0.4SE:Lower: Upper: | Mean:% mean: 40Median:SD:P:<0.0001 | Mean:Median:SD:P: | please ensure about the unit. the difference is reported for change from baseline in the vit E group only. | medium |
|  | Placebo | 48 | Mean:4.4Median SD: 0.8SE:Lower: Upper: | Mean:Median:SD:P: |
| Kim 201035 crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | 5μl of 10 μM ADP | Mean: 63Median SD: 18.9SE:Lower: Upper: | Mean:-3.6% mean: Median:SD:P: | Mean:Median:SD:P: | Mean ratio of ginkgo/No treatment: 1.02 | mediummedium |
|  | No treatment  | 24 | Mean:64.8Median SD: 19.7SE:Lower: Upper: | Mean:-3.5Median:SD:P: |
| Kim 201035 crossover | Low and/or Moderate | Ticlopidine | 250- single dose | ginkgo biloba | 24 | 1 μL of 2 μg/mL collagen | Mean: 80.4Median SD: 11.2SE:Lower: Upper: | Mean:3.5% mean: Median:SD:P: | Mean:Median:SD:P: | Mean ratio of ginkgo/No treatment: 1.03 | medium |
|  | No treatment  | 24 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Jiang 200433 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Ginseng | 12 | Arachidonic acid10 ml of 50 mM concentration | Mean: 7.1Median SD: 1.4SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:1Median:SD:P: | 95% CI of mean for individual group data: Ginseng group: 6-7.8; St. Johns Wort: 6.5-8.2; No treatment group: 5.6-9.1  | medium |
|  | St. John’s | 12 | Mean: 7.5Median SD: 1.1SE:Lower: Upper: | Mean:% mean: Median:SD:P: |
|  | No treatment | 12 | Mean:7.7Median SD: 2.2SE:Lower: Upper: | Mean:Median:SD:P: |
| Jiang 200532 | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Gingko Biloba | 12 | Arachidonic acid | Mean: 8.4Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:1.14Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 7.60-9.20; Ginger group: 7.50-8.70; No treatment group: 6.50-8.40 | medium |
|  | Ginger | 12 | Mean: 8.1Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: |
|  | No treatment | 12 | Mean:7.5Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 10μM ADP | Mean: 77Median SD: 20SE:7Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 39.00-73.00; No treatment group: 36.00-82.00 | medium |
|  | No treatment  | 10 | Mean:59Median SD: 13SE:10Lower: Upper: | Mean:Median:SD:P: |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 10μM ADP | Mean: 56Median SD: 19SE:7Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 61.00-92.00; No treatment group: 41.00-79.00. | medium |
|  | No treatment  | 10 | Mean:60Median SD: 23SE:8Lower: Upper: | Mean:Median:SD:P: |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 5μM ADP | Mean: 57Median SD: 22SE:8Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 39.00-75.00 p-value <0.05; No treatment group: 23.00-72.00, p-value <0.05.  | medium |
|  | No treatment  | 10 | Mean:47Median SD:32 SE:11Lower: Upper: | Mean:Median:SD:P: |
| Aruna 20072crossover | At low risk for CHD (0-1 risk factors) | Cilostazol 100 mg | 104 to 200 (cilostazol); 75 to 150 (clopidogrel) | ginkgo biloba | 10 | 2.5μl of 5μM ADP | Mean: 49Median SD: 21SE:8Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | 95% CI of mean for individual group data: ginkgo group: 31.00-67.00, p-value <0.05; No treatment group: 30.00-73.00, p-value < 0.05.  | medium |
|  | No treatment  | 10 | Mean:52Median SD: 26SE:9Lower: Upper: | Mean:Median:SD:P: |
| Mohammed Abdul 200849Crossover | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Garlic | 12 | assessed on blood samples (within 3 h of blood collection) collected 24 h prior to warfarin administration ( 24 h) in each treatment period using a whole blood aggregometer (Chrono-par; Chrono-log Corp., Havertown, Pennsylvania, USA; Edward Keller Australia Pty Ltd, Hallam, VIC, Australia). Method described further but not extracted | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | "…2 weeks of pretreatment with garlic…had no effect on platelet aggregation." | medium |
|  | No treatment | 12 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| McKenney 200645Crossover | Low and/or Moderate | simvastatin | 80 | Omega-3  | 24 | ADP | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: -3.4Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | No treatment | 23 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean -4.5Median:SD:P: |
| McKenney 200645Crossover | Low and/or Moderate | simvastatin | 80 | Omega-3  | 24 | Collagen  | Mean: Median SD: SE:Lower: Upper: | Mean:% mean:-5.1 Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | No treatment | 23 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean -6Median:SD:P: |
| Abdul 20101  | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | 10μM ADP | Mean: 7.5Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:0.84Median:SD:P: | Post treatment mean 95% CI: Echinacea group 4.1-10.8; No treatment group 5.5-10.  | medium |
|  | No treatment | 11 | Mean:7.8Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Abdul 20101  | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | Arachidonic acid0.5mM | Mean: 12.1Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:1.06Median:SD:P: | Post treatment mean 95% CI: Echinacea group 9.3-15; No treatment group 9.6-12.5.  | medium |
|  | No treatment | 11 | Mean:11Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Abdul 20101  | At low risk for CHD (0-1 risk factors) | Warfarin | 25 - single dose | Echinacea | 11 | Collagen-induced2μg/ml | Mean:15.8Median SD: SE:Lower: Upper: | Mean:Median:SD:P: | Mean:1Median:SD:P: | Post treatment mean 95% CI: Echinacea group 12.2-19.5; No treatment group 11.5-14.6.  | medium |
|  | No treatment | 11 | Mean:13Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |  |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Collagen-inducedat 7 days after treatment | Mean: 81Median SD: 8.6SE:Lower: Upper: | Mean:% mean: -5.6Median:SD:P: | Mean:Median:SD:P: | ratio of means presented with 90% CI | medium |
|  | Placebo | 50 | Mean:81Median SD: 12.7SE:Lower: Upper: | Mean:% mean: -3.5Median:SD:P: |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Adenosine diphosphate-inducedat day 7 after treatment | Mean: 44.8Median SD: 18.1SE:Lower: Upper: | Mean:% mean: -26.9Median:SD:P: | Mean:0.95Median:SD:P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:47.2Median SD: 15.1SE:Lower: Upper: | Mean:% mean: -25.4Median:SD:P: |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Arachidonate-inducedat day 7 after treatment | Mean: 2.2Median SD: 2.1SE:Lower: Upper: | Mean:% mean: -76Median:SD:P: | Mean:0.65Median:SD:P: | ratio of means reported with 90% CI; 100 put in as top of 90% CI but actually infinity | low-medium |
|  | Placebo | 50 | Mean:3.4Median SD: 10.4SE:Lower: Upper: | Mean:% mean:-75.1Median:SD:P: |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Ristocetin-inducedat 7 days, after treatment | Mean: 90Median SD: 10.5SE:Lower: Upper: | Mean:% mean: -6.5Median:SD:P: | Mean:0.98Median:SD:P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:92.2Median SD: 12.3SE:Lower: Upper: | Mean:% mean:-4.1Median:SD:P: |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Epinephrine-inducedat 7 days after treatment | Mean: 13.7Median SD: 7.7SE:Lower: Upper: | Mean:-7.1% mean: Median:SD:P: | Mean:0.99Median:SD:P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:13.8Median SD: 6.8SE:Lower: Upper: | Mean:% mean:-6.5Median:SD:P: |
| Wolf 200668 crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | 50 | Platelet-activating factor-inducedat day 7 after treatment | Mean: 4.8Median SD: 3.7SE:Lower: Upper: | Mean:% mean: -22.3Median:SD:P: | Mean:0.69Median:SD:P: | ratio of means reported with 90% CI | low-medium |
|  | Placebo | 50 | Mean:6.9Median SD: 11.5SE:Lower: Upper: | Mean:% mean:-23.2Median:SD:P: |
|  | Placebo | 50 | Mean:Median SD: SE:Lower: Upper: | Mean:% mean:Median:SD:P: |